Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Watson Pharmaceuticals has reached a settlement with Ireland-based Elan Corporation on outstanding patent litigation related to Watson's generic version of Naprelan tablets.
Subscribe to our email newsletter
Under the terms of the agreement, Watson will pay Elan $18 million in full settlement of all disputes related to Watson’s development, manufacturing, marketing and sale of its Naprelan (naproxen sodium) product.
Watson has also agreed not to market or sell its naproxen sodium product until the expiration or final finding of invalidity or unenforceability of US patent number 5,637,320. Other details concerning the settlement have not been disclosed.